EUCTR2013-005062-19-AT进行中（未招募）1 期
An exploratory study to evaluate dermal open flow microperfusion’s (dOFM) ability to assess bioequivalence and non-bioequivalence of topical acyclovir formulations in healthy volunteers
Medical University of Graz - Division of Endocrinology and Metabolism0 个研究点目标入组 56 人开始时间: 2014年12月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent must be obtained before any assessment is performed.
- •2. Male and female subjects 21 to 50 years of age inclusive and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •3. Able to communicate well with the investigator, to understand and comply with the requirements of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 56
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
- •2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
- •3. Use of topical corticosteroids or systemic immunosuppression within the last 3 weeks (for topicals) or 3 months (systemic medication)
- •4. A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening or baseline.
- •PR > 220 msec
- •QRS complex > 120 msec
- •Long QT syndrome
- •QTcF > 430 msec males, > 450 females
- •5. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 10 mIU/mL).
- •6. Significant medical problems, including but not limited to the following: uncontrolled hypertension (=160 systolic /95 diastolic mm Hg), congestive heart failure [New York Heart Association status of class III or IV].
- •7. Screening total WBC count <3,500cells/µL, or platelets <140,000cells/µL or neutrophils ?2,000cells/µL or hemoglobin <12 g/dL / <13.5g/dL for female / male.
- •8. Active systemic infections during the last two weeks (exception: common cold) prior to enrollment.
- •9. A febrile illness within 72 hours, or major dental work within 8 days, prior to first dosing.
- •10. History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
- •11. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- •12. Inability or unwillingness to undergo repeated catheterization and / or venipuncture (e.g., because of poor tolerability or lack of access to veins). Inability or unwillingness of having a skin biopsy if consent was given.
- •13. Any medical or psychiatric condition or clinical laboratory abnormalities which, in the Investigator’s opinion, would interfere with interpretation of study results and/or make the participant likely not to adhere to the protocol or complete the study per protocol.
- •14. History of venous thrombosis or known genetic predisposition to thromboembolic events
- •15. Subjects prone to keloid or hypertrophic scar formation or any wound healing disorder as visible by checking the vaccine insertion points on upper arm.
- •16. Fear of needles (belonophobia)
- •17. Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc).
- •18. Not willing to avoid excessive sun exposure, steam baths, sauna, swimming and other strenuous activities during the study to ensure good scarring
研究者
相似试验
已完成
不适用
Bioequivalence of Topical Acyclovir in Healthy VolunteersDermatologic DisordersNCT02711267Medical University of Graz36
已完成
4 期
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic DermatitisDermatitis AtopicNCT04718870Sanofi41
已完成
4 期
Dupilumab Skin Barrier Function Study in Atopic DermatitisAtopic DermatitisNCT04447417Sanofi52
撤回
不适用
A pilot study for measurement of potential dermal and inhalation exposure during pouring a liquid antimicrobial pesticide productn.a.niet van toepassingNL-OMON30096American Chemistry Council2
已完成
不适用
Intraoperative evaluation of free flap blood flow during head and neck reconstruction surgery using indocyanine green near infrared angiographyHead and neck cancerJPRN-UMIN000020353Kanazawa University10